Assembly Biosciences Inc Cash Flow Conversion Efficiency
Assembly Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Assembly Biosciences Inc (ASMB) has a cash flow conversion efficiency ratio of -0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.49 Million) by net assets ($305.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Assembly Biosciences Inc (2008–2025)
Cash flow conversion efficiency of Assembly Biosciences Inc from 2008 to 2025. This chart illustrates how Assembly Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ASMB stock price for real-time trading data and today's change.
Assembly Biosciences Inc Cash Flow Conversion Ratio Explained
Assembly Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Assembly Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Assembly Biosciences Inc ranked by their cash flow conversion efficiency. Also see market value of Assembly Biosciences Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Genesco Inc
NYSE:GCO
|
0.314x |
|
Kura Sushi USA Inc
NASDAQ:KRUS
|
0.045x |
|
Regal Partners Global Investments Limited
AU:RG1
|
0.053x |
|
Voneseals Technology (Shanghai) Inc. A
SHE:301161
|
0.015x |
|
Jiangsu Hengshang Energy Conservation Technology Co. Ltd. A
SHG:603137
|
N/A |
|
Shanghai Hollywave Electronic System Co. Ltd. A
SHG:688682
|
-0.012x |
|
Wolfspeed, Inc.
NASDAQ:WOLF
|
-0.005x |
|
Lendingtree Inc
NASDAQ:TREE
|
0.091x |
Annual Cash Flow Conversion Efficiency for Assembly Biosciences Inc (2008–2025)
The table below shows the annual cash flow conversion efficiency of Assembly Biosciences Inc from 2008 to 2025. Review how much free cash does Assembly Biosciences Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $206.75 Million | $-41.09 Million | -0.199x | +87.03% |
| 2024-12-31 | $33.36 Million | $-51.12 Million | -1.532x | -376.89% |
| 2023-12-31 | $41.10 Million | $22.74 Million | 0.553x | +154.16% |
| 2022-12-31 | $82.66 Million | $-84.46 Million | -1.022x | -84.81% |
| 2021-12-31 | $168.93 Million | $-93.40 Million | -0.553x | -111.27% |
| 2020-12-31 | $240.58 Million | $-62.96 Million | -0.262x | +14.95% |
| 2019-12-31 | $273.22 Million | $-84.07 Million | -0.308x | +0.22% |
| 2018-12-31 | $210.65 Million | $-64.96 Million | -0.308x | -1975.30% |
| 2017-12-31 | $113.12 Million | $1.86 Million | 0.016x | +103.77% |
| 2016-12-31 | $79.88 Million | $-34.88 Million | -0.437x | -177.33% |
| 2015-12-31 | $118.74 Million | $-18.70 Million | -0.157x | +38.41% |
| 2014-12-31 | $58.57 Million | $-14.97 Million | -0.256x | +64.81% |
| 2013-12-31 | $24.49 Million | $-17.80 Million | -0.727x | +39.48% |
| 2012-12-31 | $17.81 Million | $-21.38 Million | -1.200x | -65.36% |
| 2011-12-31 | $34.53 Million | $-25.07 Million | -0.726x | -61.86% |
| 2010-12-31 | $11.63 Million | $-5.21 Million | -0.449x | -272.03% |
| 2009-12-31 | $-13.36 Million | $-3.48 Million | 0.261x | -40.55% |
| 2008-12-31 | $-9.46 Million | $-4.15 Million | 0.439x | -- |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase … Read more